• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19 有症状住院患者的死亡:高危患者的影响。

Death among patients hospitalized with symptomatic COVID-19: Implications for high-risk patients.

机构信息

Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts, USA.

Department of Medicine, University of Massachusetts Chan Medical School-Baystate, Springfield, Massachusetts, USA.

出版信息

J Hosp Med. 2022 Apr;17(4):252-258. doi: 10.1002/jhm.12805. Epub 2022 Mar 16.

DOI:10.1002/jhm.12805
PMID:35535924
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9088345/
Abstract

BACKGROUND

We aimed to examine the role played by the COVID-19 infection in patients' death and to determine the proportion of patients for whom it was a major contributor to death.

METHODS

We included patients ≥50 years old who were hospitalized with COVID-19 infection and died between March 1, 2020 and September 30, 2020 in a tertiary medical center. We considered COVID-19 infection to be a major cause for death if the patient had well-controlled medical conditions and death was improbable without coronavirus infection, and a minor cause for death if the patient had serious illnesses and had an indication for palliative care.

RESULTS

Among 243 patients, median age was 80 (interquartile intervals: 72-86) and 40% were female. One in two had moderate or severe frailty and 41% had dementia. Nearly 60% of the patients were classified as having advanced, serious illnesses present prior to the hospitalization, with death being expected within 12 months, and among this group 39% were full code at admission. In the remaining 40% of patients, deaths were classified as unexpected based on patients' prior conditions, suggesting that COVID-19 infection complications were the primary contributor to death.

CONCLUSIONS

For slightly less than half (40%) of patients who died of complications of COVID-19, death was an unexpected event. Among the 60% of patients for whom death was not a surprise, our findings identify opportunities to improve end-of-life discussions and implement shared decision-making in high-risk patients early on or prior to hospitalization.

摘要

背景

我们旨在研究 COVID-19 感染在患者死亡中的作用,并确定其是导致患者死亡的主要原因的比例。

方法

我们纳入了 2020 年 3 月 1 日至 2020 年 9 月 30 日期间在一家三级医疗中心住院的 COVID-19 感染且死亡的≥50 岁患者。如果患者的医疗状况得到良好控制,且没有冠状病毒感染则死亡的可能性较小,则认为 COVID-19 感染是导致死亡的主要原因;如果患者患有严重疾病且需要姑息治疗,则认为 COVID-19 感染是导致死亡的次要原因。

结果

在 243 名患者中,中位年龄为 80 岁(四分位间距:72-86),40%为女性。近一半(50%)患者有中度或重度衰弱,41%有痴呆。近 60%的患者被归类为患有在住院前存在的晚期、严重疾病,预计在 12 个月内死亡,其中 39%在入院时是全面复苏(指除心肺复苏外,还包括脑复苏等一系列复苏措施);在其余 40%的患者中,根据患者先前的病情,死亡被归类为意外事件,这表明 COVID-19 感染并发症是导致死亡的主要原因。

结论

对于近一半(40%)死于 COVID-19 并发症的患者,死亡是一个意外事件。对于 60%的死亡并非意料之中的患者,我们的研究结果确定了机会,可以改善高危患者的临终讨论,并在早期或在住院前就实施风险共担决策。

相似文献

1
Death among patients hospitalized with symptomatic COVID-19: Implications for high-risk patients.COVID-19 有症状住院患者的死亡:高危患者的影响。
J Hosp Med. 2022 Apr;17(4):252-258. doi: 10.1002/jhm.12805. Epub 2022 Mar 16.
2
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
3
Development of Severe COVID-19 Adaptive Risk Predictor (SCARP), a Calculator to Predict Severe Disease or Death in Hospitalized Patients With COVID-19.严重 COVID-19 适应性风险预测器(SCARP)的开发,是一种用于预测 COVID-19 住院患者发生严重疾病或死亡的计算器。
Ann Intern Med. 2021 Jun;174(6):777-785. doi: 10.7326/M20-6754. Epub 2021 Mar 2.
4
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.用于评估非住院轻中度 COVID-19 患者肠道微生物组调节的自然史和影响的虚拟化临床研究:一项随机、开放标签、前瞻性研究,平行组研究评估 KB109 对肠道微生物组结构和功能的生理影响:一项随机对照研究方案的结构化总结。
Trials. 2021 Apr 2;22(1):245. doi: 10.1186/s13063-021-05157-0.
5
Clinical Characteristics and Outcome of Hospitalized COVID-19 Patients in a MERS-CoV Endemic Area.在中东呼吸综合征冠状病毒流行地区住院的 COVID-19 患者的临床特征和转归。
J Epidemiol Glob Health. 2020 Sep;10(3):214-221. doi: 10.2991/jegh.k.200806.002.
6
Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.2021 年 7 月 15 日至 9 月 23 日和 2021 年 12 月 21 日至 2022 年 1 月 27 日期间,加利福尼亚州一家医院因实验室确诊的 SARS-CoV-2 感染住院的成年人的临床特征和结局,期间 B.1.617.2(德尔塔)和 B.1.1.529(奥密克戎)变异株占主导地位。
MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):217-223. doi: 10.15585/mmwr.mm7106e2.
7
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.在纽约市地区,5700 名因 COVID-19 住院的患者的特征、合并症和结局。
JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775.
8
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗(灭活,Vero 细胞)有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
9
Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19.癌症病史对 COVID-19 住院患者结局的影响。
Oncologist. 2021 Aug;26(8):685-693. doi: 10.1002/onco.13794. Epub 2021 May 12.
10
Increased Incidence of In-Hospital Ischemic Stroke During SARS-CoV-2 Outbreak: A Single-Center Study.新冠病毒爆发期间住院缺血性脑卒中发病率增加:一项单中心研究。
Neurocrit Care. 2022 Feb;36(1):208-215. doi: 10.1007/s12028-021-01286-1. Epub 2021 Jul 15.

引用本文的文献

1
Estimates of population-level palliative care need in the UK: a descriptive analysis of mortality data before and during the COVID-19 pandemic.英国人群中对姑息治疗需求的评估:COVID-19 大流行前后的死亡率数据分析描述
BMC Palliat Care. 2024 Nov 25;23(1):271. doi: 10.1186/s12904-024-01574-5.
2
Risk Factors Associated with Severity and Death from COVID-19 in Iran: A Systematic Review and Meta-Analysis Study.伊朗 COVID-19 严重程度和死亡的相关风险因素:系统评价和荟萃分析研究。
J Intensive Care Med. 2023 Sep;38(9):825-837. doi: 10.1177/08850666231166344. Epub 2023 Mar 28.
3
Improving goal-concordant care in the hospital for patients with dementia in the COVID-19 era.在新冠疫情时代改善医院对痴呆症患者的目标一致护理。
J Hosp Med. 2022 May;17(5):412-413. doi: 10.1002/jhm.12817. Epub 2022 Apr 11.

本文引用的文献

1
Different aspects of frailty and COVID-19: points to consider in the current pandemic and future ones.衰弱的不同方面与 COVID-19:当前大流行及未来需考虑的要点。
BMC Geriatr. 2021 Jun 27;21(1):389. doi: 10.1186/s12877-021-02316-5.
2
Frailty as a predictor of mortality among patients with COVID-19: a systematic review and meta-analysis.衰弱作为 COVID-19 患者死亡率的预测指标:系统评价和荟萃分析。
BMC Geriatr. 2021 Mar 17;21(1):186. doi: 10.1186/s12877-021-02138-5.
3
COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis.COVID-19 住院患者病死率:系统评价和荟萃分析。
Ann Epidemiol. 2021 May;57:14-21. doi: 10.1016/j.annepidem.2021.02.012. Epub 2021 Mar 2.
4
Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study.4244 例危重症 COVID-19 成年患者的临床特征和第 90 天结局:一项前瞻性队列研究。
Intensive Care Med. 2021 Jan;47(1):60-73. doi: 10.1007/s00134-020-06294-x. Epub 2020 Oct 29.
5
COVID-19 pandemic: triage for intensive-care treatment under resource scarcity (3rd, updated version).新型冠状病毒肺炎疫情:资源稀缺情况下的重症监护治疗分诊(第三版,更新版)
Swiss Med Wkly. 2020 Nov 12;150:w20401. doi: 10.4414/smw.2020.20401. eCollection 2020 Nov 2.
6
Ejection fraction and mortality: a nationwide register-based cohort study of 499 153 women and men.射血分数与死亡率:一项基于全国登记的 499153 名女性和男性的队列研究。
Eur J Heart Fail. 2021 Mar;23(3):406-416. doi: 10.1002/ejhf.2047. Epub 2020 Nov 26.
7
Prognostic value of the Surprise Question for one-year mortality in older patients: a prospective multicenter study in acute geriatric and cardiology units.《Surprise 问题对老年患者一年内死亡率的预后价值:急性老年科和心脏病科的前瞻性多中心研究》
Acta Clin Belg. 2022 Apr;77(2):286-294. doi: 10.1080/17843286.2020.1829869. Epub 2020 Oct 12.
8
Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters.大流行中心非老年人群和非老年无基础疾病人群的 COVID-19 总体人群死亡率风险。
Environ Res. 2020 Sep;188:109890. doi: 10.1016/j.envres.2020.109890. Epub 2020 Jul 1.
9
Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study.10021 例新冠肺炎住院患者的病例特征、资源利用和结局:一项观察性研究。
Lancet Respir Med. 2020 Sep;8(9):853-862. doi: 10.1016/S2213-2600(20)30316-7. Epub 2020 Jul 28.
10
The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study.衰弱对 COVID-19 患者生存的影响(COPE):一项多中心、欧洲、观察性队列研究。
Lancet Public Health. 2020 Aug;5(8):e444-e451. doi: 10.1016/S2468-2667(20)30146-8. Epub 2020 Jun 30.